Mark Baker

1.9k total citations
22 papers, 757 citations indexed

About

Mark Baker is a scholar working on Public Health, Environmental and Occupational Health, Infectious Diseases and Oncology. According to data from OpenAlex, Mark Baker has authored 22 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Public Health, Environmental and Occupational Health, 7 papers in Infectious Diseases and 5 papers in Oncology. Recurrent topics in Mark Baker's work include Malaria Research and Control (10 papers), HIV/AIDS drug development and treatment (6 papers) and HIV/AIDS Research and Interventions (5 papers). Mark Baker is often cited by papers focused on Malaria Research and Control (10 papers), HIV/AIDS drug development and treatment (6 papers) and HIV/AIDS Research and Interventions (5 papers). Mark Baker collaborates with scholars based in Switzerland, United Kingdom and United States. Mark Baker's co-authors include Martina Hagen, Jörg J. Möhrle, Peter O’Rourke, Louise Marquart, James McCarthy, Paul Griffin, Rob Hooft van Huijsduijnen, Stephan Duparc, Nicholas J. White and Mallika Imwong and has published in prestigious journals such as Nature Communications, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Mark Baker

21 papers receiving 738 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Baker Switzerland 14 403 155 141 131 113 22 757
K Na‐Bangchang Thailand 19 645 1.6× 230 1.5× 263 1.9× 57 0.4× 119 1.1× 45 866
J Karbwang Thailand 16 589 1.5× 193 1.2× 375 2.7× 111 0.8× 83 0.7× 29 859
F. Joel Leong Singapore 9 334 0.8× 168 1.1× 54 0.4× 58 0.4× 93 0.8× 11 467
Isabelle Borghini-Fuhrer Switzerland 14 577 1.4× 229 1.5× 223 1.6× 83 0.6× 95 0.8× 24 832
Joël Mosnier France 18 485 1.2× 210 1.4× 135 1.0× 109 0.8× 247 2.2× 50 964
Sarah Arbe‐Barnes Switzerland 10 571 1.4× 251 1.6× 129 0.9× 60 0.5× 105 0.9× 16 880
A Thanavibul Thailand 16 616 1.5× 176 1.1× 281 2.0× 60 0.5× 79 0.7× 34 757
S Krudsood Thailand 21 614 1.5× 150 1.0× 111 0.8× 49 0.4× 117 1.0× 32 826
Robert Mull Switzerland 16 667 1.7× 256 1.7× 296 2.1× 73 0.6× 98 0.9× 30 1.1k
P.A. Winstanley United Kingdom 17 994 2.5× 170 1.1× 260 1.8× 117 0.9× 191 1.7× 33 1.4k

Countries citing papers authored by Mark Baker

Since Specialization
Citations

This map shows the geographic impact of Mark Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Baker more than expected).

Fields of papers citing papers by Mark Baker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Baker. The network helps show where Mark Baker may publish in the future.

Co-authorship network of co-authors of Mark Baker

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Baker. A scholar is included among the top collaborators of Mark Baker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Baker. Mark Baker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thakkar, Nilay, Rulan Griesel, Amy Pierce, et al.. (2025). Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV. Infectious Diseases and Therapy. 14(6). 1313–1326. 2 indexed citations
2.
Thakkar, Nilay, Rulan Griesel, Amy Pierce, et al.. (2025). Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV. Infectious Diseases and Therapy. 14(5). 1011–1025. 2 indexed citations
3.
Patel, Parul, Marta Boffito, Joseph W. Polli, et al.. (2023). Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine. Therapeutic Advances in Infectious Disease. 10. 2018449442–2018449442. 4 indexed citations
4.
Patel, Parul, Susan L. Ford, Mark Baker, et al.. (2022). Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials. HIV Medicine. 24(5). 568–579. 32 indexed citations
5.
Krystal, Mark, Daren Austin, Max Lataillade, et al.. (2022). A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection. Antiviral Therapy. 27(5). 3867489135–3867489135. 1 indexed citations
6.
Wattanakul, Thanaporn, Mark Baker, Brett McWhinney, et al.. (2021). Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria. Antimicrobial Agents and Chemotherapy. 65(4). 4 indexed citations
7.
Baker, Mark, Bassel Abou‐Khalil, Amir Arain, et al.. (2018). Lacosamide efficacy and tolerability in clinical practice – Post marketing analysis from a single dedicated epilepsy center. Clinical Neurology and Neurosurgery. 171. 179–183. 5 indexed citations
8.
Hagen, Martina & Mark Baker. (2017). Skin penetration and tissue permeation after topical administration of diclofenac. Current Medical Research and Opinion. 33(9). 1623–1634. 103 indexed citations
9.
McCarthy, James, Mark Baker, Peter O’Rourke, et al.. (2016). Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers. Journal of Antimicrobial Chemotherapy. 71(9). 2620–2627. 51 indexed citations
10.
McCarthy, James, Thomas Rückle, Cathy Cantalloube, et al.. (2016). A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. Malaria Journal. 15(1). 469–469. 81 indexed citations
11.
McCarthy, James, Louise Marquart, Silvana Sekuloski, et al.. (2016). Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development. Antimicrobial Agents and Chemotherapy. 60(6). 3669–3675. 28 indexed citations
12.
Pasay, Cielo, Rebecca J. Rockett, Silvana Sekuloski, et al.. (2016). Piperaquine Monotherapy of Drug-SusceptiblePlasmodium falciparumInfection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia. The Journal of Infectious Diseases. 214(1). 105–113. 48 indexed citations
13.
Phyo, Aung Pyae, Podjanee Jittamala, François Nosten, et al.. (2015). Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. The Lancet Infectious Diseases. 16(1). 61–69. 127 indexed citations
14.
Okell, Lucy, Matthew Cairns, Jamie T. Griffin, et al.. (2014). Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. Nature Communications. 5(1). 5606–5606. 71 indexed citations
15.
Morris, Carrie A., Stephen R. Dueker, Liquan Wang, et al.. (2014). Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics. 40(1). 75–86. 14 indexed citations
16.
17.
Baker, Mark, Jörg J. Möhrle, & Daren Austin. (2012). Lost in translation? Bridging the preclinical / clinical divide. Malaria Journal. 11(S1). 2 indexed citations
18.
Baker, Mark, et al.. (2007). Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake. Xenobiotica. 37(10-11). 1110–1134. 72 indexed citations
19.
Christensen, Hege, Mark Baker, Geoffrey T. Tucker, & Amin Rostami‐Hodjegan. (2006). Prediction of Plasma Protein Binding Displacement and its Implications for Quantitative Assessment of Metabolic Drug–Drug Interactions from In Vitro Data. Journal of Pharmaceutical Sciences. 95(12). 2778–2787. 29 indexed citations
20.
Baker, Mark, et al.. (2000). . BDJ. 188(5). 288–288.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K Na‐Bangchang Breakdown of academic impact, for papers by J Karbwang Breakdown of academic impact, for papers by F. Joel Leong Breakdown of academic impact, for papers by Isabelle Borghini-Fuhrer Breakdown of academic impact, for papers by Joël Mosnier Breakdown of academic impact, for papers by Sarah Arbe‐Barnes Breakdown of academic impact, for papers by A Thanavibul Breakdown of academic impact, for papers by S Krudsood Breakdown of academic impact, for papers by Robert Mull Breakdown of academic impact, for papers by P.A. Winstanley
Rankless by CCL
2026